APG Asset Management N.V. Sells 45,951 Shares of Boston Scientific Corporation $BSX

APG Asset Management N.V. reduced its holdings in Boston Scientific Corporation (NYSE:BSX) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 975,266 shares of the medical equipment provider’s stock after selling 45,951 shares during the quarter. APG Asset Management N.V. owned 0.07% of Boston Scientific worth $91,080,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the first quarter worth about $27,000. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific during the fourth quarter worth about $25,000. Colonial Trust Co SC grew its holdings in shares of Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 260 shares in the last quarter. Sunbeam Capital Management LLC bought a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Finally, Ameriflex Group Inc. bought a new position in shares of Boston Scientific during the fourth quarter worth about $31,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock worth $35,976,603 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $105.9950 on Friday. The stock has a market cap of $157.06 billion, a P/E ratio of 63.09, a PEG ratio of 2.53 and a beta of 0.66. The stock has a 50 day simple moving average of $104.10 and a 200 day simple moving average of $102.16. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1-year low of $78.53 and a 1-year high of $108.94.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the firm posted $0.62 EPS. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BSX. UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Morgan Stanley increased their price target on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, May 16th. Robert W. Baird increased their price target on Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Erste Group Bank raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, May 8th. Finally, Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.